CAS: 1023595-17-6; (1H-Indazol-4-yl)Boronic Acid
该化合物是一种环流碳酸衍生物,广泛用作铃木-宫浦交叉相交反应中的关键中间体,其丁二醇核心和丙烯酸功能组可高效生成催化氨酸丙烯-氨酸,使其在制药和材料科学研究中具有价值.该化合物在标准处理条件下具有良好稳定性,并表现出与各种卤化亚醇的高度反应性,便于合成复杂的双子体结构.它与各种反应条件和功能组的兼容性增强了其在药用化学中的效用,有助于建造类似药物的手脚架.建议在惰性条件下适当储存,以保持其活性和储量寿命.
相似化合物
885618-33-7 885068-10-0 338454-14-1物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS07;
注释: Exclamation mark - 危险类别特定目标器官毒性 - 单次接触 类别3
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2
急性毒性 类别4(经口)
急性毒性 类别4(吸入)
急性毒性 类别4(经皮)
严重眼刺激 类别2A - 警示词Warning(警告)
- 危险描述H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H302 |吞咽有害.
H332 |吸入有害.
H312 |皮肤接触有害. - 防范说明P261-P264-P271-P280-P302+P352-P304+P340-P362+P364-P405-P501
- UN编号NONH for all modes of transport
- 危险品标志Xi
- 安全声明26-36-36/37/39-22
- 危险类别码36/37/38-22
- WGK Germany3
欧盟法规
C&L通报上下游产品
boric acid tributyl ester2-amino-6-(1H-indazol-4-yl)-3-phenyl-4(3H)-quinazolinone合成工艺路线路线简述
📜硼酸三丁酯,4-Bromo-1-(Triisopropylsilyl)-1H-Indazole置于正丁基锂体系中,化学反应 0.5H,以72%的收率获得1H-吲唑-4-硼酸
参考文献:一种氮未取代吡唑和吲唑类硼酸的制备方法
标题:一种氮未取代吡唑和吲唑类硼酸的制备方法
摘要:一种氮未取代吡唑和吲唑类硼酸的制备方法,以氮未取代卤代吡唑及其衍生物或氮未取代卤代吲唑及其衍生物和三异丙基氯硅烷溶于有机溶剂中进行反应,生成三异丙基硅基保护的卤代吡唑或者卤代吲唑化合物,再与正丁基锂发生锂溴交换反应,加入硼酸酯引入硼原子,水解后高收率的到得了氮未取代吡唑或吲唑类硼酸.
专利信息
专利号:US-2025026766-A1
优先权日:2022-01-12
标题 :Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors
发明人：LI JING; XU WENQING; WANG ZHIWEI
权利人:BEIGENE LTD
摘要:The present invention relates to compounds containing thiazolopyridyl amide structure, the process for their synthesis, as well as the use of such compounds for inhibiting DNA Polymerase Theta (Pol Theta), and in the treatment of various diseases including cancers.
专利号:US-8791131-B2
优先权日:2008-09-30
标题 :Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
发明人：CHENG HENGMIAO; JOHNSON TED WILLIAM; HOFFMAN JACQUI ELIZABETH; GUO LISA CHEN; LIU ZHENGYU
权利人:CHENG HENGMIAO; JOHNSON TED WILLIAM; HOFFMAN JACQUI ELIZABETH; GUO LISA CHEN; LIU ZHENGYU; PFIZER
摘要:The present invention is directed to compounds of Formula (I), n nand to salts thereof, their synthesis, and their use as PI3-Kα inhibitors and/or PI3-Kα/mTOR dual inhibitors.
